Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development

作者：Parikh Sameer A; Litzow Mark R^*

来源：Future Oncology, 2014, 10(14): 2201-2212.

DOI：10.2217/fon.14.81

• chimeric antigen receptor therapy
• immunotoxin
• NOTCH1 inhibitors
• novel monoclonal antibodies
• proteasome inhibitors

Although the prognosis of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) has steadily improved over the past decade, less than 50% of patients maintain their remission at 5 years. Several approaches have been explored in the past few years including: monoclonal antibodies - either naked' (rituximab) or in combination with an immunotoxin (calicheamicin or maytansin), plant toxin (ricin), or bacterial toxin (Pseudomonas or diphtheria), and a novel bispecific T-cell-engaging antibody (blinatumomab); chimeric antigen therapy using autologous T cells that target CD19-expressing ALL; and novel agents such as proteasome inhibitors, liposomal vincristine, hypomethylating agents, nelarabine and NOTCH1 inhibitors. This review summarizes treatment approaches currently under investigation for the treatment of adult Philadelphia chromosome-negative ALL.

• 出版日期2014